R&D/Clinical Trials

Tracking the pandemic’s influence on brand awareness and prescribing efforts in light of decline in physician visits and fewer diagnoses—and what these dynamics, still unsettled post-pandemic, might mean for future launches.

Launch of novel drug for rare neuromuscular disorder seeks to give voice to the patients.

Use against pair of pathways could pave way for standout in stocked eye disease market.

Tapping the potential of new market mindset in insomnia—delivering a quality next day.

Dual-targeted injection poised to rock GLP-1 field in diabetes—and eventually weight loss.

More favorable administration, reimbursement could separate latest PCSK9 entrant.

Failed efforts do not overshadow field’s progress, resolve.

Innovative and continuous remote patient monitoring, along with AI-based predictive analytics, are advancing progress toward replacing the one-size-fits-all, population-driven vaccination model.

The road to precision medicine as a fixture in healthcare delivery is still a journey, but recent advances and new understandings in gene profiling, biomarker development, and AI and data analytics are steadily bringing these therapies closer to the individual patient every day.

Pharma companies may benefit from meeting challenges and embracing small molecule drug discovery.

Dr. Kyle Flanigan, Ph.D., discusses the benefits of an oral COVID-19 vaccine.

Has data science finally reached a level playing field with all of the science data being uncovered in the make, test, decide innovation cycle?

Kobel discusses taking a company public during a challenging time in the market.

Amidst lack of funding for women’s health research, industry must collaborate now to advance RMMH.

As director of corporate strategy for Novartis, Kamenska defines direction for the company’s overall enterprise. Here, she discusses how the pandemic and recent market events are shaping these strategies.

Larger pipeline and increased support from regulatory authorities are setting up the orphan drug market for long-term success.

Industry must continue research and development to combat the pandemic.

Makar discusses the significance of AstraZeneca’s diabetes and heart failure drug Forxiga (dapagliflozin) for the treatment of chronic kidney disease (CKD).

Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.

Survey taken by pharma and CRO executives evaluates attributes of large datasets.

Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.

Szwarcberg discusses challenges in the rare disease drug development space, and how his background is helping him find solutions for patients, specifically with endocrine disorders.

Its use enables key processes such as early access, regulatory approval, and reimbursement listing.

Improvements in R&D, manufacturing, and data sharing will extend platform’s reach.

Pharm Exec speaks with Ambrogio about the struggles the industry faces in regard to developing cures for rare cancers, and how Bayer is using precision medicine to meet these challenges.

Pharm Exec speaks with Adams about how his company developed a new medicine designed to meet migraine patients’ needs.

Industry has shown it can overcome challenges en route to creating new therapies.

New mediums of technology must be utilized correctly to reap full benefits.

From exposing disparities in care to guiding better patient outcomes to helping reign in the costs of care, the use of real-world data (RWD) in oncology can have far-reaching effects. Here’s how one RWD company exec is using her experience to help drive that change.

With added push from the COVID-19 pandemic, investment in promising RNA- and cell and gene therapy-based treatments and technology via industry dealmaking is growing considerably.